JPMorgan Chase & Co. set a €105.00 ($123.53) price target on MorphoSys (ETR:MOR) in a research report sent to investors on Tuesday morning, Borsen Zeitung reports. The brokerage currently has a buy rating on the stock.
A number of other analysts also recently weighed in on the company. Berenberg Bank set a €140.00 ($164.71) target price on MorphoSys and gave the company a buy rating in a research report on Thursday, May 6th. Barclays set a €90.00 ($105.88) price objective on shares of MorphoSys and gave the stock a neutral rating in a research note on Thursday, June 3rd. Deutsche Bank Aktiengesellschaft set a €116.00 ($136.47) target price on shares of MorphoSys and gave the company a buy rating in a research report on Thursday, June 3rd. Independent Research set a €95.00 ($111.76) price target on shares of MorphoSys and gave the stock a buy rating in a report on Wednesday, March 17th. Finally, The Goldman Sachs Group set a €75.00 ($88.24) price objective on shares of MorphoSys and gave the company a neutral rating in a research note on Tuesday, May 11th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company has a consensus rating of Buy and an average price target of €105.13 ($123.68).
Shares of ETR:MOR opened at €69.90 ($82.24) on Tuesday. The business’s 50 day moving average is €72.33. MorphoSys has a 1 year low of €60.30 ($70.94) and a 1 year high of €125.20 ($147.29). The company has a quick ratio of 6.06, a current ratio of 6.22 and a debt-to-equity ratio of 55.32. The firm has a market capitalization of $2.29 billion and a P/E ratio of -16.51.
MorphoSys AG, together with its subsidiaries, discovers, develops and commercializes therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia.
Read More: EV Stocks
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.